Eastern Canada Cutaneous Research Associates Ltd. Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Halifax Canada (2003)

Organization Overview

First Clinical Trial
2004
NCT00244842
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Alternative names

Eastern Canada Cutaneous Research Associates, LTD

Active Ingredients

Drugs in Phase 3 Trials (5)

betamethasone (celestone) (1 trial)

calcipotriene (dovonex) (1 trial)

calcipotriol (1 trial)

tacalcitol (1 trial)

voclosporin (Lupkynis) (2 trials)

Drugs in Phase 2 Trials (1)

nb-002 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Onychomycosis (Phase 2)

Psoriasis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 6